Known Benefits of Cartilade

Potential Applications

Cartilade contains the essential components for overall joint health. Several human and animal pilot studies confirm the benefits of Cartilade in joint and connective tissues health. New research regarding Cartilade show that it has been proven to be the superior brand of cartilage powder as demonstrated by in vitro assay. Cartilade has been demonstrated to be completely safe when used as directly and over 500 million doses have been used worldwide. Cartilade is appropriate for adults and children over 12 year of age.

Potential Mode of Action

In addition to glycosaminoglycans, proteins such as collagen and elastin, Cartilade® inhibits the enzymatic activity of MMP. MMPs represent a special class of catabolic enzymes that target and cleave fibrous proteins of the extracellular matrix. Cartilade supports the delicate balance of the destruction activity of connective tissues by MMP enzymes and the reconstruction of the same tissues.

Angiogenesis and its Relationship to Cancer and Other Degenerative Diseases

Angiogenesis is a natural physiological function. It refers to the process by which new blood vessels form and grow. Angiogenesis is also involved in the progression of different diseases. Cancerous tumors, for example, require a network of blood vessels to act as conduits for oxygen and nutrients. In addition, this vascular network allows cancerous cells to invade the rest of the body, a process called metastasis.

Angiogenesis inhibitors block the formation of these new blood vessels. Without the nourishment these blood vessels supply, cancerous cells are starved, and tumors cannot grow.

How Angiogenesis Promotes the Development of Cancer

Angiogenesis performs a critical role in the development of cancer.

Solid tumors smaller than 1 to 2 cubic millimeters are not vascularized. To spread, they need to be supplied by blood vessels that bring oxygen and nutrients and remove metabolic wastes.

Beyond the critical volume of 2 cubic millimeters, oxygen and nutrients have difficulty diffusing to the cells in the center of the tumor, causing a state of cellular hypoxia that marks the onset of tumbrel angiogenesis.

New blood vessel development is an important process in tumor progression. It favors the transition from hyperplasia to neoplasm i.e. the passage from a state of cellular multiplication to a state of uncontrolled proliferation characteristic of tumor cells.

Neovascularization also influences the dissemination of cancer cells throughout the entire body eventually leading to metastasis formation. The vascularization level of a solid tumor is thought to be an excellent indicator of its metastatic potential.

Role of Angiogenesis in Psoriasis

Chronic inflammation of the tissue underlying the epidermis in psoriatic skin creates a strong angiogenic signal. Several studies have shown a high detectable blood flow in the psoriatic plaques.

The inducing factors for new blood vessels depends, among other things, on many angiogenic growth factors. These are present in psoriatic patches and produced by keratinocytes.

This supports observations that the psoriasis initiating factor resides in the keratinocyte and that a significant vascular proliferation is required to cause hyperplasia of the epidermis. Hence, inhibiting neovascularization would be an indirect means of counteracting psoriatic plaque formation. Shark cartilage, a angiogenesis inhibitor is currently being studied as potential therapy for psoriasis.

More than six million people suffer from psoriasis in North America. Up to 250,000 new cases are diagnosed every year. The overall cost of treating psoriasis in the United States is about $3 billion to $5 billion per year.

Current systemic treatments for psoriasis have significant side effects. The most used treatments for psoriasis are topical applications. Current treatments include keratolytic agents, corticosteroids, tar (especially coal tar), vitamin D3 derivatives, anthralin and topical antimitotic agents. These treatments, however, are often messy, have an unpleasant odor, and are repetitive and tedious for patients.

More practical systemic treatments are riskier due to potential side effects. The most common is the antimitotic agent, methotrexate. Other treatments are PUVA and UVBs. Some combination of phototherapy and another antipsoriatic agent can be used. All of these treatments have side effects of varying significance. Using antiangiogenic agents to treat psoriasis is a relatively new approach.*

Shark Cartilage as an Angiogenesis Inhibitor and Potential Aid in the Fight Against Cancer and other Angiogenesis-Dependent Diseases

As early as the 1970s, Dr. Judah Folkman of the Harvard Medical School suggested inhibiting new blood vessel formation as a way to fight cancer.

In 1983, two researchers at the Massachusetts Institute of Technology published a study showing that shark cartilage contains a substance that significantly inhibits the development of blood vessels that nourish solid tumors, thereby limiting tumor growth.

Working independently, medical researchers at Harvard University Medical School found that if one could inhibit angiogenesis--the development of a new blood network--one could prevent the development of tumor-based cancer and metastasis.

In his book, SHARKS DON'T GET CANCER--HOW SHARK CARTILAGE COULD SAVE YOUR LIFE, Dr. I. William Lane ties together these two important findings regarding shark cartilage and angiogenesis. Dr. Lane also recounts his own involvement in the search for a truly effective treatment of tumor-based cancer and examines the work of researchers who have conducted studies that indicate that shark cartilage can be effective in reducing cancer related tumors and also reduce the inflammation and pain associated with other conditions, such as arthritis, psoriasis and enteritis.

Because there are so many cancer victims who have been advised, after undergoing "conventional" treatments--surgery, radiation, or chemotherapy--that there is nothing more conventional medicine can do for them, it is clear that research into alternative approaches, such as shark cartilage, should be explored.

Indeed, given the fact that shark cartilage has no toxic side-effects, those who have been advised that conventional medicine can do nothing more to help them have little to lose by exploring shark cartilage as an alternative.

Shark Cartilage: "What Are the Theories for Prevention and Treatment of Cancer and Other Diseases Involving Neovascularization?"

Recently, shark cartilage has generated intense interest in both public and medical circles because of the theoretical justification for its clinical use in diseases, including cancer, psoriasis, age-related macular degeneration and arthritis, which involve neovascularization (angiogenesis). This interest is further fueled by clinical trials and recent patents which have demonstrated its anti-tumor activity and its ability to relieve pain and inflammation associated with tumor activity and diseases involving angiogenesis.

While there are many publications outlining the theories supporting why scientists believe shark cartilage has so many therapeutic benefits, public interest in shark cartilage was first generated by writings and research first tied together by Dr. I. William Lane. We have asked Dr. Lane, and he has been gracious enough to allow us to reprint one of his early papers on the therapeutic benefits of shark cartilage. This article, which follows, is not nearly as informative as his book, SHARKS DON'T GET CANCER. However, in this relatively-brief article, Dr. Lane provides a cogent summary of much of the early research and many of the theories on the therapeutic benefits of shark cartilage.

Shark Cartilage Therapy -- A Personal History of it's Development*
I. William Lane, Ph.D.

The use of shark cartilage in the complementary treatment of non-responsive solid cancer tumors has become widely used worldwide; approximately 25,000 patients are using the therapy today. Initially, shark cartilage usage was strictly patient-driven, but more recently it is suggested by doctors when conventional cancer therapies have not helped patients. Certainly, most oncologists will agree that, despite the progress in treating cancer, the lack of a real breakthrough is frustrating and many oncologists state they themselves would not use chemotherapy if they develop cancer. In fact, many calls that come in to me are from physicians on behalf of themselves or members of their families. Yet, they are reluctant to recommend shark cartilage to patients because of concerns relating to malpractice suits. The book Sharks Don't Get Cancer, which I coauthored, is now published in more than 15 languages and has been widely read, and the therapeutic regimen is followed by countless people who felt hopeless about surviving their cancers. I like to think that the correct, and I must stress the word correct, use of a good shark cartilage, in adequate dosage levels, has helped thousands of such patients. Shark cartilage therapy has caught the attention of all levels of practitioners, but it is hard for many of them to believe that so simple an approach can work with such a stubborn disease. However, despite the controversy, many who have tried and correctly used shark cartilage are talking about it in highly positive terms.

Much more research has been undertaken than most people realize and the undisputable fact is that the Food and Drug Administration (FDA)--after carefully weighing the clinical evidence--has recently granted full Investigational New Drug (IND) permission for phase 2 clinical trials on both advanced nonresponsive prostate cancer as well as on advanced Kaposi's sarcoma. This lends material credence to the work. These phase 2 trials will soon be under way in one of the most prestigious medical centers in the Midwest. To date, I have personally funded the research, so inexpensive facilities and groups had to be found. Still, the unusually large and long positive responses should partially offset the lack of peer review.

This history of my work with shark cartilage as well as the benchmarks that originally opened the door of my curiosity will explain why and how interest developed. As a student at Cornell and later at Rutgers I had the good fortune to be exposed to the thinking of two Nobel Laureates, James B. Sumner, Ph.D., and Selman Waksman, M.D., Ph.D. I learned to look for the unusual and ask "Why?" As a so-called fisheries expert, I first became interested in the shark when the Shah of Iran asked me to look into developing, for him, a possible fishery in the Persian Gulf, an area that abounds in shark. As I read and inquired about the topic, it became obvious that this incredible living machine called shark had survived literally unchanged for 300 million years; it was a prehistoric creature, and it rarely got cancer even though almost all other sea creatures get a lot of cancer, especially since pollution of the oceans has increased materially.

The "Why?" was partially answered when I met, and read the work of, John Prudden, M.D., who was working with bovine cartilage as an immune stimulator, wound healing, and anticancer agent. However, the real "Why?" was answered when, in 1983, Anne Lee, Ph.D., and Robert Langer, Ph.D.,5 published a paper that illustrated that shark cartilage inhibited angiogenesis and tumor growth. I learned of this study via CNN NEWS, which, along with many popular newspapers and TV programs, publicized this incredible response. I immediately visited Dr. Langer at Massachusetts Institute of Technology and he told me that, although his work was done with a complex extract, whole but undenatured shark cartilage would probably produce an even better effect. Dr. Langer later denied having this conversation, but it took place in his office in September 1983 and it was the starting point of my piqued interest. I then read much of the work of Judah Folkman, M.D., on the theory of inhibiting angiogenesis as a mechanism to stop tumor growth. I also read the work of another Harvard researcher which said that the avascular tissues were the logical place to find the angiogenic inhibitors. Based on the published work just cited and my own desire to develop a practical "how and why," the concept behind the shark cartilage product developed.